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Down-regulation of hepatic LDL receptor expression in experimental
nephrosis. Nephrotic syndrome (NS) is invariably associated with eleva-
tion of plasma total and LDL cholesterol concentrations. The present
study was carried Out to test the hypothesis that nephrotic LDL hyper-
cholesterolemia is, in part, due to acquired LDL receptor (LDLR)
deficiency. To this end, hepatic LDLR mRNA (Northern blot analysis)
and protein mass (Western blot analysis) were measured longitudinally
before and during the course of puromycin-induced NS. In addition, the
rate of LDLR gene transcription by isolated hepatic nuclei was deter-
mined using nuclear run-on assay. Hepatic LDLR mRNA remained
virtually unchanged during the 30-day course of the study period. How-
ever, after an insignificant rise on day 5, LDLR protein mass gradually
declined to a level which was significantly below the baseline values (P <
0.05 ANOVA). This was accompanied by a normal rate of LDLR mRNA
synthesis excluding impaired gene transcription as a cause. The fall in
hepatic LDLR protein was associated with a marked rise in plasma total
and LDL cholesterol concentrations but no rise in hepatic tissue choles-
terol concentration. The latter observation is indicative of impaired
hepatic cholesterol uptake and provides functional evidence for the
demonstrated acquired LDLR deficiency in the NS animals. Likewise, our
findings elucidate the molecular basis of the previously reported impaired
LDL clearance in NS. In conclusion, severe hypercholesterolemia in rats
with experimental NS is associated with and perhaps, in part, is due to
down-regulation of LDL receptor expression.
Nephrotic syndrome (NS) is invariably accompanied by ele-
vated plasma total and low-density lipoprotein (LDL) cholesterol
concentrations [1—4]. These abnormalities can potentially contrib-
ute to cardiovascular complications and progressive renal insuffi-
ciency [5—10]. According to earlier studies, LDL synthesis is
increased [4], and LDL clearance is decreased in NS [9]. Plasma
LDL concentration is a function of the rates of LDL synthesis and
catabolism. Normally, 60 to 80% of LDL and 50% of VLDL are
cleared by the liver primarily via LDL receptor (LDLR) mediated
endocytosis. Thus, hepatic LDLR-mcdiated clearance plays a
major role in LDL-cholesterol catabolism [11—14]. Primary LDLR
deficiency in familial hypercholesterolemia is associated with
severe hypercholesterolemia [15]. In an earlier study, Warwick et
a! demonstrated a marked reduction in clearance of radiolaheled
LDL in a group of patients with nephrotic syndrome [91. Based on
this observation, they concluded that impaired receptor-mediated
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LDL clearance is, in part, responsible for nephrotic hypercholes-
terolemia [9]. To our knowledge, the effect of NS on gene
expression and production of LDLR has not been directly dem-
onstrated. The present study was designed to test the hypothesis
that NS results in down-regulation of LDLR expression which, in
turn, contributes to the pathogenesis of hypercholesterolemia and
dysregulation of cholesterol synthesis and catabolism.
Methods
Study groups
Male Sprague-Dawley rats (180 to 200 g) were purchased from
Charles River Inc. (Wilmington, MA, USA) and maintained on
Purina Rat Chow (Purina Mills Inc., Brentwood, MO, USA).
They were kept in a climate-controlled space with 12-hour light
(500 lux) and 12-hour dark (5 lux) cycles. The rats were randomly
assigned to the nephrotic (NS) and normal control (NL) groups.
Animals assigned to the NS group were given intraperitoneal (i.p.)
injections of puromyein aminonucleoside (Sigma Inc., St. Louis,
MO, USA), 130 mg/kg, on day 0 and 60 mg/kg on day 14. Animals
assigned to the control group were given placebo injections. All
animals were provided free access to food and water. Subgroups
of rats were studied at baseline (day 0) and on days 1, 5, 20, and
30 after the initial puromyein injection. Under general anesthesia
(i.p. sodium pentobarbital, 50 mg/kg), the animals were sacrificed
and liver was harvested for measurements of hepatie LDLR
mRNA and protein mass. On each occasion, plasma concentra-
tions of albumin, total cholesterol, LDL cholesterol, triglycerides
and creatinine and 24-hour urinary excretion of protein and
creatinine were determined using standard laboratory techniques.
RNA preparation and Northern blot analysis
The rats were killed between the hours of 8 to 10 a.m. The liver
was removed immediately, placed in liquid nitrogen and stored at
—70°C until processed. Total RNA was prepared from I g of liver
by the guanidium thiocyanate extraction procedure as previously
described [16]. RNA concentration was determined from the
absorbance at 260 nm using a spectrophotometer. Thirty micro-
gram aliquots of total RNA were denatured in 2.2 M formaldehyde
at 65°C for 15 minutes and run on 1.2% agarose/2.2 M formalde-
hyde gel at 70 V for three hours. The separated RNA was
transferred to the nylon membrane (Zeta Probe; Bio-Rad Labo-
ratories, Inc., Hercules, CA, USA) by capillary blotting method in
6 x SSC buffer overnight and immobilized by UV irradiation
(Ultraviolet Crosslinker; Fisher Scientific, Pittsburgh, PA, USA).
The membrane was incubated at 65°C in a solution containing 5 X
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SSPE, 5 x Derihard's, 1% SDS and 100 jig/mI salmon sperm
DNA. The cDNA probe for human LDLR (1.9 Kb BamHI
fragment of PLDLR2) [17] and human /3-actin cDNA (1.1 Kb
EcoRI fragment) were obtained from American Type Culture
Collection (Rockville, MD, USA) and labeled with [32P] dCTP
(3000 Ci/mmol; New England Nuclear Inc., Boston, MA, USA) by
the random primer method (Prime-A-Gene System, Promega
Biotec Inc., Madison, WI, USA). Hybridization was carried out at
60°C overnight in prehybridization solution containing 32P-la-
beled probes. The blots were washed twice in 2 X SSPE/0.5% SDS
solution at room temperature, twice in 1 X SSPE/0.5% SDS
solution at 37°C, twice in 0.1 X SSPE/0.5% SDS solution at 65°C,
15 minutes each. The washed blots were exposed to the X-ray film
(New England Nuclear) at —80°C for six hours for actin and two
days for LDLR. The autoradiograms were scanned with a laser
densitometer (PD 1211; Molecular Dynamics, Sunnyvale, CA,
USA) to determine relative mRNA levels. The values obtained
for actin were used as internal control.
Western blot analysis
These measurements were carried out to determine the LDLR
protein mass. To this end, hepatocyte plasma membranes were
prepared as follows. Frozen rat liver was homogenized in 20 mrvi
Tris-HC1 (pH 7.5) containing 2 m'vi MgCI2, 0.2 M sucrose, 5 mM
phenylmethylsulfonyl fluoride, 5 jig/ml leupeptin, 10 jig/mI apro-
tinin and 3 jig/mI pepstatin A [181. The crude extract was
centrifuged at 3000 g for 10 minutes at 4°C. The supernatant was
then centrifuged at 35,000 g for 30 minutes. The membrane
preparation was then washed with the above buffer and centri-
fuged at 35,000 g for 45 minutes at 4°C. Protein concentration was
determined by using a Bio-Rad kit (Bio-Rad Laboratories).
One-hundred microgram protein aliquots were size fractionated
on 4 to 12% Tris-glycine gel (Novex Inc., San Diego, CA, USA) at
120 V for two hours. After electrophoresis, proteins were trans-
ferred to Hybond-ECL membrane (Amersham Life Science Inc.,
Arlington Heights, IL, USA). The membrane was incubated for
one hour in buffer A (1 X PBS, 0.1% Tween-20 and 10% nonfat
milk) and then overnight in the same buffer containing 5% nonfat
milk plus I jig/mI mouse anti-bovine LDLR antibody (Cortex
Biochem Inc., Davis, CA, USA). Membrane was washed once for
15 minutes then twice for five minutes in I X PBS, 0.1% Tween-20
prior to a one hour incubation in buffer A plus diluted (1:1000)
horseradish peroxidase-linked sheep anti-mouse IgG (Amersham
Life Science). The washes were repeated before the membranes
were developed with chemiluminescent agents (ECL; Amersham
Life Science) and subjected to autoradiography for five minutes.
Nuclear run-on assay
Nuclear run-on assay was carried out using the following steps
as previously described [19].
Isolation of ral liver nuclei. Hepatie nuclei were purified for in
vitro transcription studies. To this end, rat liver (2 g) was
homogenized in 10 volumes of buffer A (10 mrvi Tris-HCI [pH 7.I,
1 mM EDTA, 0.25 M sucrose, 5 mM MgC12) using a polytron
homogenizer (Brinkmann Instruments Inc., Westbury, NY, USA)
at setting 5 for 15 seconds. The homogenate was then centrifuged
at 800 g for 10 minutes at 4°C. The pellet was resuspended in 4 ml
of buffer A and further homogenized using a Dounce homoge-
nizer (Fisher Scientific). The homogenate was then filtered
through 2 nylon filters (pore size, 210 jim and 53 jim; Spectrum
Medical Industries Inc., Los Angeles, CA, USA) and centrifuged
at 800 g for 10 minutes at 4°C. The pellet was resuspended in
buffer A containing 0.5% Triton-100 (Sigma Inc.) and centrifuged
as before. The pellet was resuspended in 2.2 M Sucrose-Tris buffer
containing 10 mivi Tris-HCI (pH 7.4) and 5 m'vi MgCl2 layered on
2.3 M ice-cold Sucrose-Tris buffer and centrifuged at 35,000 g for
60 minutes at 4°C. The nuclei were then collected and washed in
3 ml of buffer A and suspended in a storage buffer (25% glycerol,
20 mvi Tris, 1.5 mrvi MgCl2, and 0.2 mi EDTA, pH 7.9). A
proteinase inhibitor preparation (0.2 mt PMSF, 2.5 jig/mI of
aprotinin/leupeptin; Sigma Inc.), DTT and RNasin (20 jig/mI;
Promega Biotec Inc.) were added through all steps. The concen-
tration of nuclei was measured by lyzing an aliquot of the
resuspended nuclei in 0.1% SDS and determining the absorbance
at 260 and 230 nm. The nuclei were then frozen at —70°C until
used.
Labeling and isolation of nascent RNA transcripts. Equal num-
bers of nuclei were used in transcription reaction at 26°C for 45
minutes in a 400 jil solution of 40 nM Tris-HC1 (pH 8.3), 150 mtvi
NH4C1, 7.5 m'vi MgC12, 400 ji RNasin, 2.5 ms't DTT, 0.625 mM
ATP, 0.313 mivi CTP, 0.313 m GTP (Boehringer Mannheim
Corp., Indianapolis, IN, USA) and 100 jiCi (cs-32P)UTP (3000
Ci/mmol, New England Nuclear). To block elongation of tran-
scription by RNA polymerase II, ci-amanitin (Boehringer Mann-
heim Corp.) was used at a final concentration of 2 jig/ml. The
reaction was terminated on ice, and RNase-free DNase RQ-1
(Promega Biotec Inc.) was added to reach a concentration of 100
jig/mI. After an incubation period of 10 minutes at room temper-
ature, I ml RNAzo1 (Tel-Test Inc., Friendswood, TX, USA) and
200 jil chloroform were added. The solution was vortexed and
placed on ice for 15 minutes. After centrifugation at 10,000 g for
10 minutes, the aqueous phase was removed and an equal volume
of isopropanol was added for RNA precipitation overnight at
—70°C. The precipitate was then collected by centrifugation at
14,000 g for 15 minutes and washed twice in 75% ethanol and
resuspended in DEPC water. The 32P-labeled RNA was run over
a G-25 Sephadex quick-spin RNase-free column (Boehringer
Mannheim Corp.). A I jil aliquot of eluate was counted with a
liquid scintillation counter (LS 9000; Beckman, Placentia, CA,
USA).
Hybridization. The 32P-labeled RNA solution was heated at
95°C for five minutes, then quickly chilled on ice before hybrid-
ization to specific eDNA sequences. The linearized LDL-reeeptor
(PLDLR7) eDNA and /3-actin eDNA were denatured in 0.2 M
NaOH; 5 jig of eDNA was applied to the nylon membrane and
baked at 80°C for two hours. Prehybridization of the filters was
performed for two hours at 55°C in hybridization buffer: 5 X SSC,
50% formamide, 5 X Denhard's reagent, 0.1% SDS and 200
jig/ml polyadenylic acid. An equal number of radioactive counts
of the 32P-RNA (1.5 >< 10) were added to freshly made hybrid-
ization buffer, and the mixture was incubated for 48 hours at 55°C.
After hybridization, the strips were washed twice at 55°C for 15
minutes each in 2 x SSC, 0.1% SDS and treated with RNase A
(10 jig/mI; Boehringer Mannheini Corp.) at 37°C for 30 minutes,
then washed with 2 x SSC twice at 37°C. Radioactive RNA bound
to the various filters was quantitated by liquid scintillation count-
ing. The values were corrected for nonspecific binding measured
in the blank filters.
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Table 1. Plasma concentrations of albumin and creatinine, 24-hour urinary protein excretion and creatinine clearance at baseline (day 0) and on
days 1, 5, 20 and 30 post-initial puromycin injections
Day 0
(N_=_6)
Day I
(N_=_6)
Day 5
(N_=_6)
Day 20
(N = 6)
Day 30
(N = 6)
P
values
Plasma albumin mg/dl 3.4 0.1 3.8 0.1 2.1 0.12 2.0 0.11 2.3 0.22 0.001
Urine protein mg/24 hrs 7.6 0.7 7.2 1.4 170 14.3 258 32 213 18 0.001
Plasma creatinine mg/dl 0.62 0.06 0.56 0.07 0.66 0.08 0.67 0.07 0.65 0.08 NS
Creatinine clearance mI/mm 1.2 0.1 1.15 0.15 1.0 0.10 1.2 0.11 1.3 0.16 NS
Data are expressed as mean SEM.
P 0.001 (one-way ANOVA and Student's t-test)
DO Dl D5 D20 D3O
Fig. 1. Plasma concentrations of total cholesterol ([—J), LDL cholesterol([. J), and triglycerides (f-.- —. ]) at baseline (DO) and on days
1, 5, 20 and 30 (Dl, D5, D20 and D30). A minimum of six rats were studied
at each point. Data are given as mean SEM. *P < 0.001 (multiple
measure ANOVA).
Statistical analyses
Multiple measure analysis of variance (ANOVA), Students'
t-test and regression analysis were used in statistical evaluation of
the data which are expressed as mean SEM. P values equal to or
less than 0.05 were considered significant.
Results
General findings
Data are depicted in Table 1 and Figure 1. The NS group
exhibited marked proteinuria and hypoalbuminemia beyond day 5
of puromycin administration. This was accompanied by severe
elevations of plasma total cholesterol and LDL-cholesterol con-
centrations and a modest rise in plasma triglyceride concentration
(Fig. 1). Plasma LDL cholesterol concentration directly correlated
with urinary protein excretion (r = 0.85, P < 0.001) and negatively
correlated with plasma albumin concentration (r = —0.89, P <
0.001; Fig. 2). No significant difference was found in hepatic tissue
cholesterol concentration between the NS and the normal control
groups (Fig. 3). There was no significant difference in serum
creatinine concentration between the NS and the normal control
group. Likewise, creatinine clearance values were comparable in
the two groups.
0
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Plasma LDL cholesterol, mg/dI
Fig. 2. Correlations between plasma LDL cholesterol concentration (r =
—0.89, P < 0.001) and urinary protein excretion (r = 0.85, P < 0.001) in the
nephrotic ( and normal control (•) groups obtained dunng the study
period.
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Data are shown in Figures 4, 5 and 6. No significant difference
was observed in hepatic LDLR mRNA levels between the normal
control group and the subgroups of the NS animals studied at days
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Fig. 3. Comparison of plasma and hepatic tissue cholesterol concentrations
in the nephrotic (NS) animals (day 30) and the normal control group (NL).
Data are given as mean SE.M (N = 6 in each group). *P < 0.00!.
1, 5, 20 or 30. Thus, LDLR mRNA levels remained virtually
unchanged during the induction (days 1 to 20) and chronic phase
(day 30) of puromycin-induced NS. In contrast, after an insignif-
icant rise at day 5, hepatic LDLR protein measured by Western
blot gradually declined during the observation period reaching its
lowest point on day 30 (P < 0.05 ANOVA). There was no
significant change in either hepatic LDLR mRNA or protein 24
hours after puromycin injection (Figs. 4 and 7). This observation
tends to exclude the possible acute effect of puromycin on LDLR
protein production in the study animals. Plasma LDL cholesterol
concentration was inversely related to hepatic LDLR level (r =
0.80, P < 0.01; Fig. 8).
LDLR gene transcription rate
In an attempt to explore the cause of depressed LDLR protein
expression in the NS animals, we measured the rate of LDLR
gene transcription using isolated liver nuclei in a nuclear run-on
assay. The results are depicted in Table 2. As can be seen, the rate
of LDLR gene transcription in the NS group was similar to that
found in the normal control group. This finding excludes impaired
gene transcription as a cause of the LDLR deficiency in the NS
animals.
Fig. 4. A. A representative autoradiograph of the Northern blot of hepatic
LDL receptor (LDLR) and the cotresponding actin in the normal control
(NL) (lane 1) and the nephrotic rats (NS) at days 5 (lane 2), 20 (lane 3), and
30 (lane 4) in the course of induction of nephrosis with two puromycin-
aminonucleoside injections given on days 0 and 14. Total RNA (30 g/!ane)
was isolated from liver, as described under the Methods section, and
separated by electrophoresis on 1.2 agarose/2.2 M formaldehyde gel. RNA
was transferred to a nylon filter and hybridized with the 32P-labeled 1.9 Kb
eDNA to human LDLR mRNA and 1.1 Kb eDNA to human -actin
mRNA used to control for possible variations in the loading dose. B.
Longitudinal measurements of LDLR mRNA (normalized against corre-
sponding actin mRNA) in the norma! control (NL, N = 6) and subgroups
of ncphrotic (NS, N 6 in each subgroup) animals studied at the above
time points. Data are given as mean SEM.
Fig. 5. A representative autoradiograph of the Western blot of hepatic LDL
receptor (LDLR) in the normal control (NL) (lane 1) and the subgroups of
nephrotic rats studied at days I (lane 2), 5 (lane 3), 20 (lane 4), and 30 (lane
5) in the course of induction of nephrosis with two puromycin-aminonucleo-
side injections given on days 0 and 14. Hepatocyte plasma membrane (100
jig/lane) was isolated from liver as described under the Methods Section,
and separated by eleetrophoresis on 4 to 12% Tgris-g!ycine gel. Protein
was transferred to Hybond-ECL membrane and hybridized with I jig/mI
mouse anti-bovine LDLR.
Discussion
The occurrence of proteinuria and hypoalbuminemia in rats
assigned to the NS group was accompanied by an expected rise in
plasma total cholesterol and LDL-cholesterol concentrations. The
elevation of total and LDL-cholestcrol levels in the study animals
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Fig. 6. Longitudinal measurements of LDLR protein in the normal control(•, N = 6) and subgroups of nephrotic (U) rats studied at baseline (day 0)
and on days 1, 5, 20 and 30 (N = 6 at each time point). Data are given as
mean SEM. p < 0.05 (multiple measure ANOVA).
was associated with a normal hepatic tissue cholesterol concen-
tration. The normality of hepatic tissue cholesterol concentration
despite severe hypercholesterolemia suggests that hepatic uptake
of LDL particles may be defective in the NS animals. If true,
impaired receptor-mediated hepatic uptake, which is a major
pathway of LDL catabolism, may, iii part, contribute to the
associated hypercholesterolemia. In addition, such a defect may
play a role in dysregulation of hepatic cholesterol biosynthesis [20,
21] and catabolism [22] in this model. In this regard, we have
found an inappropriately elevated HMG-CoA reductase, an in-
appropriately depressed hepatic cholesterol 7a-hydroxylase, and a
normal hepatic tissue cholesterol concentration in animals with
NS as compared to the control animals with equally severe dietary
hypercholesterolemia. In contrast to the NS animals, the latter
animals exhibited a markedly increased hepatic cholesterol con-
centration, an appropriate down-regulation of HMG-CoA reduc-
tase and upregulation of cholesterol 7a-hydroxylasc [21, 221.
Dysregulations of HMG-CoA reductase and cholesterol 7a-hy-
droxylase in the NS animals was thought to be, in part, related to
the disproportionately low intracellular-to-plasma cholesterol
concentration ratio. This is because intracellular rather than
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Fig. 7. A. A representative Northern blot of hepatic LDL receptor (LDLR)
and the corresponding actin in the normal control (lane 1, NL) and at 24
hours after puromycin (130 mg/kg) injection (Dl). B. Comparison of hepatic
LDLR/actin mRNA obtained before and 24 hours after puromycin
injection (N = 6 in each group). Data are given as mean SEM.
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Fig. 8. Correlation between plasma LDL cholesterol concentration and
hepatic LDL receptor (LDLR) obtained in the nephrotic (U) (day 30) and
the normal control (•) groups (r = 0.80, P < 0.01).
extracellular cholesterol modulates gene expressions of these key
enzymes in cholesterol metabolism to maintain cholesterol ho-
meostasis [23—25]. Thus, if present, impaired hepatic LDL uptake
precludes appropriate down-regulation of endogenous production
$
U U.
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Table 2. Relative transcription rates of the hepatic LDL receptor gene
and -actin gene in normal control (NL) and nephrotic (NS) rats
Counts/minute
hybridized to
PLDLR2
eDNA
_______ PLDLR2/-actin
______
per 10 cpm total RNA cDNA (ratio)
NL 720 87 772 109 0.95 0.02
NS 856 26 947 33 0.91 0.04
Counts hybridized to specific eDNA sequences were corrected by
subtracting background counts hybridized to filter containing the vector
DNA (PcD). The results are expressed as mean SEM (N = 6, P> 0.1).
(via inhibition of HMG-CoA reductase) and up-regulation of
catabolism (via stimulation of cholesterol 7a-hydroxylase) of
cholesterol, steps which are necessary for mitigating the associ-
ated hypercholesterolemia. This scheme has been clearly shown to
be operative in the pathogenesis of familial hypercholesterolemia
which is caused by a genetic defect of LDLR production [151.
In an attempt to test the hypothesis that the receptor-mediated
hepatic LDL uptake may be impaired in NS, we measured LDLR
mRNA and protein mass longitudinally at baseline and during the
course of puromycin-induced NS in rats. LDLR mRNA remained
virtually unchanged throughout the course of the observation
period. Interestingly, however, LDLR protein mass gradually fell
to a level which was significantly below the baseline in the NS
animals. Accordingly, NS in this model resulted in a down-
regulation of LDLR protein mass. Plasma LDL cholesterol
concentration was inversely related to hepatic LDLR values. This
observation suggests the role of acquired LDLR deficiency in the
pathogenesis of LDL hypercholesterolemia in this model of NS as
convincingly demonstrated with primary LDLR deficiency in
familial hypercholesterolemia [15]. In order to determine the
mechanism of the observed LDLR deficiency, we compared the
rates of LDLR gene transcription by the liver nuclei isolated from
the NS and the control animals on day 30 when LDLR deficiency
was clearly evident. The results showed equal rates of LDLR
mRNA synthesis in the two groups, thus excluding depressed gene
transcription as a cause. Therefore, according to our data, NS did
not affect LDLR expression at the level of transcription. The
normality of hepatic LDLR mRNA content in the face of the
normal rate of LDLR mRNA synthesis suggests that the rate of
LDLR mRNA degradation must be similarly normal in the NS
animals. The latter tends to argue against post-transcriptional
modification of LDLR in this model. Instead, either depressed
rate of translation of LDLR mRNA and/or enhanced rate of
degradation of LDLR protein must be responsible for the ob-
served abnormality. Further studies are required to explore these
possibilities.
Using radiolabeled LDL, Warwick et al demonstrated a 45%
reduction in receptor-mediated LDL clearance in a group of
patients with moderate-to-severe NS. They, therefore, concluded
that nephrotic hypercholesterolemia must be due to a combina-
tion of increased LDL production and reduced LDL clearance [91.
Down regulation of hepatic LDLR expression demonstrated here
in experimental NS provides the molecular basis for impaired
LDL clearance in patients with NS as shown by these investigators
[9].
In conclusion, animals with puromycin-induced NS exhibited a
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